June 2009
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p11
The article reports on the approval of the U.S. Food and Drug Administration (FDA) for pancreatic enzyme replacement drug Creon from Sovay. Creon is designed to treat patients having cystic fibrosis and other diseases related to pancreatic insufficiency. Further, a mixture of digestive enzymes taken from pigs' pancreas is contained in the drug.


Related Articles

  • Ultrase NDA preserves availability on regulated market. Buono, Drew // Drug Store News;5/19/2008, Vol. 30 Issue 6, p22 

    The article reports on the ban of pancreatic enzyme products by the U.S. Food and Drug Administration (FDA). Manufacturers of the said drugs are mandated to submit a new drug application (NDA) or an investigation drug application (IDA), and those who failed to do so will be banned from selling...

  • Pancreatic Drugs Need FDA Approval To Stay On Market. Hurley, Mary Lou // RN;Jul2004, Vol. 67 Issue 7, p85 

    Reports on the United States Food and Drug Administration's decision requiring manufacturers of pancreatic enzyme products (PEP) to file drug applications. Conditions treated by PEP associated with pancreatic insufficiency.

  • Gilead: aztreonam FDA approval more likely following positive recommendation.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p11 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the drug aztreonam from Gilead Sciences Inc. for the treatment of cystic fibrosis. It notes that aztreonam has the potential to provide treatment option and aims to compete with tobamycin agent. Moreover, the...

  • Vertex combo scores a broader cystic fibrosis approval. Mullard, Asher // Nature Reviews Drug Discovery;Aug2015, Vol. 14 Issue 8, p517 

    The article presents approval by the U.S. Food and Drug Administration (FDA) of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel combination drug ivacaftor plus lumacaftor developed by the pharmaceutical company Vertex Pharmaceuticals Inc.

  • Vertex Submits Application for Priority Review and Approval of KALYDECO (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p80 

    The article reports on the submission of a drug application (NDA) by Vertex Pharmaceuticals Inc. for its Kalydeco drug in the U.S. Food and Drug Administration (FDA). The company filed for an application for priority review and approval for Kalydeco as the first potential medicine to target the...

  • NEW CYSTIC FIBROSIS DRUG. WALKER, TRACEY // Managed Healthcare Executive;Oct2015, Vol. 25 Issue 10, p53 

    The article focuses on the approval of Vertex Pharmaceuticals' lumacaftor/ivacaftor (Orkambi) drug by the U.S Food and Drug Administration (FDA). Topics discussed include use of the drug for treating cystic fibrosis (CF), views of Michael J. Sax, President at Pharmacy Group LLC, on the cost of...

  • CF Patient Power Fuels Early Kalydeco Approval. Serebrov, Mari // BioWorld Insight;2/13/2012, Vol. 20 Issue 7, p3 

    The article presents information on early approval of a new drug named as Kalydeco developed by the cystic fibrosis team of Vertex Pharmaceuticals Inc. It is stated that the company harnessed the power and experience of various cystic fibrosis patients for the development of this drug which is...

  • Pharmaxis's product pipeline is progressing well.  // Australasian Biotechnology;Jul2010, Vol. 20 Issue 2, p12 

    The article deals with the achievements of the product pipeline of Pharmaxis as of July 2010. The firm has received the resubmission of its New Drug Application (NDA) for Aridol, a mannitol inhalation powder, in April after the U.S. Food and Drug Administration (FDA) sent a letter in December...

  • Cystic fibrosis drug Vertex's latest triumph. Ledford, Heidi // Nature Biotechnology;Mar2012, Vol. 30 Issue 3, p201 

    The article reports on the approval by the U.S. Food and Drug Administration on January 31, 2012 of the sale of Cambridge, Massachusetts-based firm Vertex Pharmaceutics' new Kalydeco (ivacaftort) drug to treat a rare form of cystic fibrosis. According to pediatric pulmonologist Bonnie Ramsey,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics